Table 2.
Multiple treatment comparison for efficacy based on network consistency model (OR > 1 for ORR and DCR, or an HR < 1 for PFS and OS means better anti-tumor efficacy).
| OR with 95% CI for ORR | |||||||
|---|---|---|---|---|---|---|---|
| Chemotherapy | 4.08 (3.20, 5.96) | 6.66 (3.91, 9.83) | 3.20 (1.82, 6.68) | 5.63 (2.65, 12.10) | 5.59 (2.47, 16.23) | 7.76 (4.60, 18.67) | 5.94 (3.02, 11.48) |
| 0.24 (0.17, 0.31) | 1st-generation EGFR-TKIs | 1.60 (0.85, 2.37) | 0.80 (0.44, 1.39) | 1.38 (0.61, 2.58) | 1.39 (0.58, 3.54) | 1.83 (1.11, 3.93) | 1.48 (0.75, 2.37) |
| 0.15 (0.10, 0.26) | 0.63 (0.42, 1.18) | Afatinib | 0.48 (0.26, 1.20) | 0.84 (0.38, 2.12) | 0.84 (0.36, 2.82) | 1.21 (0.67, 3.27) | 0.89 (0.43, 2.08) |
| 0.31 (0.15, 0.55) | 1.25 (0.72, 2.29) | 2.09 (0.83, 3.80) | Dacomitinib | 1.76 (0.65, 3.96) | 1.74 (0.63, 5.54) | 2.34 (1.12, 6.19) | 1.86 (0.74, 3.96) |
| 0.18 (0.08, 0.38) | 0.72 (0.39, 1.63) | 1.19 (0.47, 2.61) | 0.57 (0.25, 1.54) | Osimertinib | 1.01 (0.36, 3.48) | 1.36 (0.64, 4.21) | 1.06 (0.42, 2.64) |
| 0.18 (0.06, 0.41) | 0.72 (0.28, 1.72) | 1.20 (0.35, 2.80) | 0.57 (0.18, 1.58) | 0.99 (0.29, 2.79) | P + Gefitinib | 1.28 (0.49, 4.44) | 1.06 (0.32, 2.74) |
| 0.13 (0.05, 0.22) | 0.55 (0.25, 0.90) | 0.83 (0.31, 1.49) | 0.43 (0.16, 0.89) | 0.74 (0.24, 1.56) | 0.78 (0.23, 2.05) | PC + Gefitinib | 0.76 (0.27, 1.54) |
| 0.17 (0.09, 0.33) | 0.68 (0.42, 1.33) | 1.12 (0.48, 2.34) | 0.54 (0.25, 1.35) | 0.94 (0.38, 2.40) | 0.94 (0.37, 3.10) | 1.32 (0.65, 3.64) | Erlotinib + Bevacizumab |
| OR with 95% CI for DCR | |||||||
| Chemotherapy | 2.24 (1.31, 4.06) | 2.41 (1.08, 5.38) | 3.36 (0.87, 13.65) | 5.65 (1.37, 26.36) | 1.94 (0.32, 9.97) | 9.18 (1.40, 83.49) | 4.54 (1.23, 18.81) |
| 0.45 (0.25, 0.76) | 1st-generation EGFR-TKIs | 1.06 (0.43, 2.50) | 1.46 (0.44, 5.18) | 2.44 (0.66, 10.15) | 0.88 (0.15, 3.91) | 4.09 (0.66, 32.81) | 2.06 (0.61, 7.46) |
| 0.41 (0.19, 0.92) | 0.94 (0.40, 2.35) | Afatinib | 1.40 (0.31, 6.67) | 2.35 (0.50, 12.88) | 0.80 (0.12, 4.82) | 3.86 (0.50, 39.15) | 1.93 (0.44, 9.45) |
| 0.30 (0.07, 1.14) | 0.68 (0.19, 2.28) | 0.72 (0.15, 3.19) | Dacomitinib | 1.70 (0.27, 11.57) | 0.58 (0.07, 4.04) | 2.85 (0.29, 32.08) | 1.43 (0.24, 7.86) |
| 0.18 (0.04, 0.73) | 0.41 (0.10, 1.51) | 0.42 (0.08, 2.02) | 0.59 (0.09, 3.77) | Osimertinib | 0.35 (0.04, 2.60) | 1.64 (0.17, 19.40) | 0.84 (0.13, 5.56) |
| 0.52 (0.10, 3.10) | 1.14 (0.26, 6.62) | 1.24 (0.21, 8.26) | 1.73 (0.25, 14.84) | 2.87 (0.38, 28.00) | P + Gefitinib | 5.02 (0.44, 75.36) | 2.63 (0.35, 23.32) |
| 0.11 (0.01, 0.71) | 0.24 (0.03, 1.51) | 0.26 (0.03, 2.00) | 0.35 (0.03, 3.44) | 0.61 (0.05, 6.02) | 0.20 (0.01, 2.27) | PC + Gefitinib | 0.49 (0.04, 4.52) |
| 0.22 (0.05, 0.81) | 0.49 (0.13, 1.64) | 0.52 (0.11, 2.28) | 0.70 (0.13, 4.24) | 1.20 (0.18, 7.68) | 0.38 (0.04, 2.86) | 2.05 (0.22, 22.53) | Erlotinib + Bevacizumab |
| HR with 95% CI for PFS | |||||||
| Chemotherapy | 0.41 (0.32, 0.53) | 0.37 (0.23, 0.57) | 0.26 (0.15, 0.48) | 0.19 (0.09, 0.41) | 0.28 (0.12, 0.63) | 0.19 (0.11, 0.31) | 0.23 (0.13, 0.43) |
| 2.42 (1.87, 3.14) | 1st-generation EGFR-TKIs | 0.88 (0.56, 1.41) | 0.64 (0.37, 1.10) | 0.46 (0.22, 0.95) | 0.68 (0.31, 1.47) | 0.46 (0.29, 0.74) | 0.56 (0.32, 0.98) |
| 2.73 (1.76, 4.26) | 1.13 (0.71, 1.80) | Afatinib | 0.72 (0.36, 1.48) | 0.52 (0.22, 1.23) | 0.77 (0.31, 1.88) | 0.52 (0.27, 0.99) | 0.63 (0.31, 1.30) |
| 3.78 (2.06, 6.88) | 1.56 (0.91, 2.68) | 1.38 (0.67, 2.80) | Dacomitinib | 0.72 (0.29, 1.75) | 1.06 (0.41, 2.70) | 0.72 (0.35, 1.47) | 0.88 (0.40, 1.90) |
| 5.24 (2.46, 11.37) | 2.17 (1.06, 4.47) | 1.92 (0.81, 4.53) | 1.39 (0.57, 3.45) | Osimertinib | 1.47 (0.51, 4.22) | 1.00 (0.42, 2.36) | 1.22 (0.49, 3.02) |
| 3.56 (1.59, 8.07) | 1.47 (0.68, 3.19) | 1.30 (0.53, 3.21) | 0.94 (0.37, 2.45) | 0.68 (0.24, 1.95) | P + Gefitinib | 0.68 (0.28, 1.68) | 0.82 (0.32, 2.16) |
| 3.56 (1.59, 8.07) | 1.47 (0.68, 3.19) | 1.30 (0.53, 3.21) | 0.94 (0.37, 2.45) | 0.68 (0.24, 1.95) | 1.48 (0.59, 3.64) | PC + Gefitinib | 1.22 (0.59, 2.54) |
| 4.30 (2.35, 7.98) | 1.78 (1.02, 3.11) | 1.58 (0.77, 3.25) | 1.14 (0.53, 2.50) | 0.82 (0.33, 2.04) | 1.21 (0.46, 3.14) | 0.82 (0.39, 1.70) | Erlotinib + Bevacizumab |
| HR with 95% CI for OS | |||||||
| Chemotherapy | 1.02 (0.89, 1.16) | 0.90 (0.74, 1.09) | 0.77 (0.57, 1.04) | 0.64 (0.43, 0.96) | 0.58 (0.43, 0.78) | 0.82 (0.51, 1.33) | – |
| 0.98 (0.86, 1.12) | 1st-generation EGFR-TKIs | 0.88 (0.72, 1.08) | 0.75 (0.57, 0.99) | 0.63 (0.43, 0.92) | 0.57 (0.43, 0.75) | 0.81 (0.51, 1.28) | – |
| 1.12 (0.92, 1.35) | 1.14 (0.93, 1.39) | Afatinib | 0.86 (0.61, 1.21) | 0.71 (0.46, 1.10) | 0.65 (0.46, 0.90) | 0.92 (0.56, 1.52) | – |
| 1.30 (0.96, 1.77) | 1.33 (1.01, 1.75) | 1.17 (0.82, 1.64) | Dacomitinib | 0.83 (0.52, 1.33) | 0.76 (0.51, 1.11) | 1.07 (0.62, 1.84) | – |
| 1.56 (1.04, 2.33) | 1.59 (1.09, 2.33) | 1.40 (0.91, 2.16) | 1.20 (0.75, 1.92) | Osimertinib | 0.91 (0.56, 1.45) | 1.29 (0.71, 2.34) | – |
| 1.71 (1.29, 2.33) | 1.74 (1.34, 2.33) | 1.54 (1.11, 2.18) | 1.31 (0.90, 1.98) | 1.10 (0.69, 1.78) | PC + Gefitinib | 1.41 (0.84, 2.43) | – |
| 1.21 (0.75, 1.96) | 1.23 (0.78, 1.96) | 1.09 (0.66, 1.79) | 0.93 (0.54, 1.60) | 0.78 (0.43, 1.40) | 0.71 (0.41, 1.20) | Erlotinib + Bevacizumab | – |
CI, confidence interval; DCR, disease control rate; EGFR-TKIs, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors; HR, hazard ratio; OR, odds ratio; ORR, objective response rate; OS, overall survival; P, Pemetrexed; PC, Pemetrexed/Carboplatin; PFS, progression-free survival.